增强型ACC/AHA策略预防肥厚型心肌病高危患者心脏性猝死
该观察性纵向研究纳入2094例肥厚型心肌病患者,前瞻性采用增强型ACC/AHA危险因素算法指导ICD决策。527例植入ICD者中82例(15.6%)发生恰当ICD治疗,5年累积概率10.5%;该策略敏感性87%-95%,特异性78%,C统计量0.81。
要点
- 增强型ACC/AHA策略对HCM患者SCD事件预测敏感性高(87%-95%)。
- 植入ICD者恰当治疗率15.6%,5年累积概率10.5%。
- 该策略特异性78%,C统计量0.81,区分度良好。
核心结论
- 增强型ACC/AHA指南与实践相结合的危险因素策略可前瞻性预测几乎所有高危HCM患者的SCD事件,预防性植入ICD避免了大量灾难性心律失常事件。
研究设计与样本
- 观察性纵向研究,纳入2094例以成人为主的肥厚型心肌病患者,在大型HCM临床中心连续评估17年,前瞻性依据个体主要危险标志物及增强型ACC/AHA指南危险因素算法进行ICD决策,并完成临床结局随访。
主要发现
- 527例基于1个以上主要危险标志物植入一级预防ICD的患者中,82例(15.6%)发生装置终止的室速或室颤事件。
- 恰当ICD干预的5年累积概率为10.5%(95%CI 8.0-13.5)。
- 增强型ACC/AHA临床危险因素策略预测SCD事件的敏感性范围为87%-95%,识别无SCD事件患者的特异性为78%。
- 增强型ACC/AHA指南的C统计量为0.81(95%CI 0.77-0.85),显示良好的区分度。
关键数值与推荐
- 增强型ACC/AHA策略敏感性87%-95%,特异性78%,C统计量0.81(95%CI 0.77-0.85)。
- ICD组恰当干预5年累积概率10.5%(95%CI 8.0-13.5)。
- 欧洲心脏病学会风险评分敏感性34%(95%CI 22-44),ACC/AHA标准敏感性95%(95%CI 89-99)。
临床怎么用
- 对HCM患者采用增强型ACC/AHA危险因素算法进行SCD风险评估,可识别绝大多数高危患者并指导预防性ICD植入。
- 该策略敏感性高但特异性中等,需结合个体化评估避免过多ICD植入。
局限性
- 为单中心观察性研究,结果外推需谨慎。
- 欧洲心脏病学会风险评分为回顾性应用,可能存在偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Strategies for reliable selection of high-risk patients with hypertrophic cardiomyopathy (HCM) for prevention of sudden cardiac death (SCD) with implantable cardioverter/defibrillators (ICDs) are incompletely resolved. OBJECTIVE: To assess the reliability of SCD prediction methods leading to prophylactic ICD recommendations to reduce the number of SCDs occurring in patients with HCM. DESIGN, SETTING, AND PARTICIPANTS: In this observational longitudinal study, 2094 predominantly adult patients with HCM consecutively evaluated over 17 years in a large HCM clinical center were studied. All patients underwent prospective ICD decision making relying on individual major risk markers derived from the HCM literature and an enhanced American College of Cardiology/American Heart Association (ACC/AHA) guidelines-based risk factor algorithm with complete clinical outcome follow-up. Data were collected from June 2017 to February 2018, and data were analyzed from February to July 2018. MAIN OUTCOMES AND MEASURES: Arrhythmic SCD or appropriate ICD intervention for ventricular tachycardia or ventricular fibrillation. RESULTS: Of the 2094 study patients, 1313 (62.7%) were male, and the mean (SD) age was 51 (17) years. Of 527 patients with primary prevention ICDs implanted based on 1 or more major risk markers, 82 (15.6%) experienced device therapy-terminated ventricular tachycardia or ventricular fibrillation episodes, which exceeded the 5 HCM-related SCDs occurring among 1567 patients without ICDs (0.3%), including 2 who declined device therapy, by 49-fold (95% CI, 20-119; P = .001). Cumulative 5-year probability of an appropriate ICD intervention was 10.5% (95% CI, 8.0-13.5). The enhanced ACC/AHA clinical risk factor strategy was highly sensitive for predicting SCD events (range, 87%-95%) but less specific for identifying patients without SCD events (78%). The C statistic calculated for enhanced ACC/AHA guidelines was 0.81 (95% CI, 0.77-0.85), demonstrating good discrimination between patients who did or did not experience an SCD event. Compared with enhanced ACC/AHA risk factors, the European Society of Cardiology risk score retrospectively applied to the study patients was much less sensitive than the ACC/AHA criteria (34% [95% CI, 22-44] vs 95% [95% CI, 89-99]), consistent with recognizing fewer high-risk patients. CONCLUSIONS AND RELEVANCE: A systematic enhanced ACC/AHA guideline and practice-based risk factor strategy prospectively predicted SCD events in nearly all at-risk patients with HCM, resulting in prophylactically implanted ICDs that prevented many catastrophic arrhythmic events in this at-risk population.
引用
- Maron MS, Rowin EJ, Wessler BS, et al. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy. JAMA Cardiol. 2019. PMID: 31116360. doi:10.1001/jamacardio.2019.1391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。